HARRER ANDREA
Universitätsklinik für Neurologie
Publikationen
|
Forscherprofil
66 Publikationen
2023
Beiträge in Fachzeitschriften
Immunomodulatory Aspects of Therapeutic Plasma Exchange in Neurological Disorders-A Pilot Study.
Foettinger, F; Pilz, G; Wipfler, P; Harrer, A; Kern, JM; Trinka, E; Moser, T;
Int J Mol Sci. 2023; 24(7):
Originalarbeiten (Zeitschrift)
Revisiting the Role of the CXCL13/CXCR5-Associated Immune Axis in Melanoma: Potential Implications for Anti-PD-1-Related Biomarker Research.
Hoellwerth, M; Koelblinger, P; Lang, R; Harrer, A;
Life (Basel). 2023; 13(2):
Übersichtsarbeiten
Serum Neurofilament Light Chain as Biomarker for Cladribine-Treated Multiple Sclerosis Patients in a Real-World Setting.
Seiberl, M; Feige, J; Hilpold, P; Hitzl, W; Machegger, L; Buchmann, A; Khalil, M; Trinka, E; Harrer, A; Wipfler, P; Moser, T;
Int J Mol Sci. 2023; 24(4):
Originalarbeiten (Zeitschrift)
2022
Beiträge in Fachzeitschriften
Humoral Response to SARS-CoV-2 Antigen in Patients Treated with Monoclonal Anti-CD20 Antibodies: It Is Not All about B Cell Recovery.
Feige, J; Berek, K; Seiberl, M; Hilpold, P; Hitzl, W; Di Pauli, F; Hegen, H; Deisenhammer, F; Trinka, E; Harrer, A; Wipfler, P; Moser, T;
Neurol Int. 2022; 14(4): 943-951.
Originalarbeiten (Zeitschrift)
The CXCL13/CXCR5 Immune Axis in Health and Disease-Implications for Intrathecal B Cell Activities in Neuroinflammation
Harrer, C; Otto, F; Radlberger, RF; Moser, T; Pilz, G; Wipfler, P; Harrer, A
CELLS-BASEL. 2022; 11(17): 2649
Übersichtsarbeiten
Long-term immunological consequences of anti-CD20 therapies on humoral responses to COVID-19 vaccines in multiple sclerosis: an observational study.
Moser, T; OSullivan, C; Otto, F; Hitzl, W; Pilz, G; Schwenker, K; Mrazek, C; Haschke-Becher, E; Trinka, E; Wipfler, P; Harrer, A;
Ther Adv Neurol Disord. 2022; 15: 17562864221092092
Originalarbeiten (Zeitschrift)
Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications - A pilot study.
Moser, T; Otto, F; OSullivan, C; Hitzl, W; Pilz, G; Harrer, A; Trinka, E; Wipfler, P;
Mult Scler Relat Disord. 2022; 59: 103560
Originalarbeiten (Zeitschrift)
Misinterpretation of glioblastoma as ADEM: potentially harmful consequences of over-diagnosis of COVID-19 vaccine-associated adverse events.
O Sullivan, C; Zach, F; Moser, T; Pilz, G; Harrer, A; Trinka, E; Enzinger, C; Pfaff, JAR; Wipfler, P;
J Neurol. 2022; 269(2):616-618
Letter
2021
Beiträge in Fachzeitschriften
The CXCL13/CXCR5-chemokine axis in neuroinflammation: evidence of CXCR5+CD4 T cell recruitment to CSF
Harrer, C; Otto, F; Pilz, G; Haschke-Becher, E; Trinka, E; Hitzl, W; Wipfler, P; Harrer, A
FLUIDS BARRIERS CNS. 2021; 18(1): 40
Originalarbeiten (Zeitschrift)
Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy.
Moser, T; OSullivan, C; Puttinger, C; Feige, J; Pilz, G; Haschke-Becher, E; Cadamuro, J; Oberkofler, H; Hitzl, W; Harrer, A; Kraus, J; Trinka, E; Wipfler, P;
Biomedicines. 2021; 9(11):
Originalarbeiten (Zeitschrift)
Tetravalent Influenza Vaccine Is Not Associated With Neuroaxonal Damage in Multiple Sclerosis Patients.
Moser, T; Seiberl, M; Feige, J; Bieler, L; Radlberger, RF; OSullivan, C; Pilz, G; Harrer, A; Schwenker, K; Haschke-Becher, E; Machegger, L; Grimm, J; Redlberger-Fritz, M; Buchmann, A; Khalil, M; Kvas, E; Trinka, E; Wipfler, P;
Front Immunol. 2021; 12:718895
Originalarbeiten (Zeitschrift)
Role and Relevance of Cerebrospinal Fluid Cells in Diagnostics and Research: State-of-the-Art and Underutilized Opportunities.
Otto, F; Harrer, C; Pilz, G; Wipfler, P; Harrer, A;
Diagnostics (Basel). 2021; 12(1):
Übersichtsarbeiten
Immune phenotyping study revealing caveats regarding a switch from fingolimod to cladribine.
Radlberger, RF; Sakic, I; Moser, T; Pilz, G; Harrer, A; Wipfler, P;
Mult Scler Relat Disord. 2021; 48:102727
Originalarbeiten (Zeitschrift)
Beiträge in Sonstigen Zeitschriften
Prognostische/prädiktive und
pharmakodynamische Biomarker
Harrer, A; Kölblinger, P; Lang, R
Spectrum Dermatologie. 2021. 1: 14-15.
2020
Beiträge in Fachzeitschriften
Epitope competition and neutralizing antidrug antibodies: immune monitoring of antiprogrammed death-1 therapies and lessons learned from natalizumab.
Harrer, A; Lang, R; Kölblinger, P;
Br J Dermatol. 2020; 183(2): 404
Letter
Neurological complications associated with influenza in season 2017/18 in Austria- a retrospective single center study.
Mylonaki, E; Harrer, A; Pilz, G; Stalzer, P; Otto, F; Trinka, E; Wipfler, P;
J Clin Virol. 2020; 127: 104340
Originalarbeiten (Zeitschrift)
Chemokine CXCL13 in serum, CSF and blood-CSF barrier function: evidence of compartment restriction.
Pilz, G; Sakic, I; Wipfler, P; Kraus, J; Haschke-Becher, E; Hitzl, W; Trinka, E; Harrer, A;
Fluids Barriers CNS. 2020; 17(1): 7
Originalarbeiten (Zeitschrift)
Beyond LNB: Real life data on occurrence and extent of CSF CXCL13 in neuroinflammatory diseases.
Pilz, G; Steger, R; Wipfler, P; Otto, F; Afazel, S; Haschke-Becher, E; Trinka, E; Harrer, A;
J Neuroimmunol. 2020; 338:577087
Originalarbeiten (Zeitschrift)
Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen
Ongoing disease activity despite depletion of memory B cells under cladribine in MS: a case report.
Radlberger, RF; Moser, T; Schwenker, K; Harrer, A; Wipfler, P;
Ongoing disease activity despite depletion of memory B cells under cladribine in MS: a case report.. 2020; -ÖGN 2020 – 17. Jahrestagung der österreichischen Gesellschaft für Neurologie, Salzburg, 20.-21. September, 2020
; 20.-21.09.2020; SALZBURG.
Abstracts (Zeitschrift)
2019
Beiträge in Fachzeitschriften
Cerebrospinal fluid CXLC13 indicates disease course in neuroinfection: an observational study.
Pilz, G; Wipfler, P; Otto, F; Hitzl, W; Afazel, S; Haschke-Becher, E; Trinka, E; Harrer, A;
J Neuroinflammation. 2019; 16(1): 13
Originalarbeiten (Zeitschrift)
2017
Beiträge in Fachzeitschriften
From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch.
Harrer, A; Pilz, G; Oppermann, K; Sageder, M; Afazel, S; Haschke-Becher, E; Rispens, T; de Vries, A; McCoy, M; Stevanovic, V; Hitzl, W; Trinka, E; Kraus, J; Sellner, J; Wipfler, P;
Clin Immunol. 2017; 176: 87-93.
Originalarbeiten (Zeitschrift)
Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen
The immune receptor expression pattern in peripheral-blood associated with JCV seropositivity in patients with multiple sclerosis is not affected by natalizumab
Harrer, A; Frommrich, M; Moser, T; Afazel, S; Haschke-Becher, E; Wipfler, P; Sellner, J
MULT SCLER J. 2017; 23: 337-338.
Abstracts (Zeitschrift)
2016
Beiträge in Fachzeitschriften
Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German-Austrian retrospective multicenter study in patients with a clinically isolated syndrome.
Huss, AM; Halbgebauer, S; Öckl, P; Trebst, C; Spreer, A; Borisow, N; Harrer, A; Brecht, I; Balint, B; Stich, O; Schlegel, S; Retzlaff, N; Winkelmann, A; Roesler, R; Lauda, F; Yildiz, Ö; Voß, E; Muche, R; Rauer, S; Bergh, FT; Otto, M; Paul, F; Wildemann, B; Kraus, J; Ruprecht, K; Stangel, M; Buttmann, M; Zettl, UK; Tumani, H;
J Neurol. 2016; 263(12):2499-2504
Originalarbeiten (Zeitschrift)
Human Cerebrospinal Fluid Promotes Neuronal Viability and Activity of Hippocampal Neuronal Circuits In Vitro
Perez-Alcazar, M; Culley, G; Lyckenvik, T; Mobarrez, K; Bjorefeldt, A; Wasling, P; Seth, H; Asztely, F; Harrer, A; Iglseder, B; Aigner, L; Hanse, E; Illes, S
FRONT CELL NEUROSCI. 2016; 10:
Originalarbeiten (Zeitschrift)
Human Cerebrospinal Fluid Promotes Neuronal Viability and Activity of Hippocampal Neuronal Circuits In Vitro (vol 10, 54, 2016)
Perez-Alcazarl, M; Culleyl, G; Lyckenvik, T; Mobarrez, K; Bjorefeldt, A; Wasling, P; Seth, H; Asztely, F; Harrer, A; Iglseder, B; Aignerxxx, L; Hansel, E; Illes, S
FRONT CELL NEUROSCI. 2016; 10: 227
Korrekturen
Basophil Reactivity as Biomarker in Immediate Drug Hypersensitivity Reactions-Potential and Limitations.
Steiner, M; Harrer, A; Himly, M;
Front Pharmacol. 2016; 7: 171
Übersichtsarbeiten
Elevated Toll-Like Receptor-Induced CXCL8 Secretion in Human Blood Basophils from Allergic Donors Is Independent of Toll-Like Receptor Expression Levels.
Steiner, M; Hawranek, T; Schneider, M; Ferreira, F; Horejs-Hoeck, J; Harrer, A; Himly, M;
PLOS ONE. 2016; 11(2): e0149275
Originalarbeiten (Zeitschrift)
The Evolution of Human Basophil Biology from Neglect towards Understanding of Their Immune Functions.
Steiner, M; Huber, S; Harrer, A; Himly, M;
Biomed Res Int. 2016; 2016: 8232830
Übersichtsarbeiten
CD1d expression on chronic lymphocytic leukemia B cells affects disease progression and induces T cell skewing in CD8 positive and CD4CD8 double negative T cells.
Zaborsky, N; Gassner, FJ; Asslaber, D; Reinthaler, P; Denk, U; Flenady, S; Hofbauer, JP; Danner, B; Rebhandl, S; Harrer, A; Geisberger, R; Greil, R; Egle, A;
Oncotarget. 2016; 7(31):4945-49469
Originalarbeiten (Zeitschrift)
2015
Beiträge in Fachzeitschriften
High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis.
Harrer, A; Pilz, G; Wipfler, P; Oppermann, K; Sellner, J; Hitzl, W; Haschke-Becher, E; Afazel, S; Rispens, T; van der Kleij, D; Trinka, E; Kraus, J;
Clin Exp Immunol. 2015; 180(3):383-392
Originalarbeiten (Zeitschrift)
Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.
Harrer, A; Wipfler, P; Pilz, G; Oppermann, K; Haschke-Becher, E; Afazel, S; Kraus, J; Trinka, E; Sellner, J;
Int J Mol Sci. 2015; 16(9): 21832-21845.
Originalarbeiten (Zeitschrift)
Serial flow cytometric analyses of blood and cerebrospinal fluid in natalizumab-associated progressive multifocal leukencephalopathy with an excellent outcome
Pilz, G; Harrer, A; Wipfler, P; Oppermann, K; Sellner, J; Rispens, T; van der Kleij, D; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J;
Clinical and Experimental Neuroimmunology. 2015;
Fallberichte
2014
Beiträge in Fachzeitschriften
TaqManR proximity ligation technology for the detection of heterodimeric adhesion receptors on lymphocytes.
Gehwolf, R; Band, E; Trost, A; Iglseder, B; Trinka, E; Haschke-Becher, E; Kraus, J; Harrer, A;
J Immunol Methods. 2014; 404:81-86
Originalarbeiten (Zeitschrift)
High-dose intravenous interferon-beta in multiple sclerosis patients with high-titer neutralizing antibodies (HINABS II) - A pilot study.
Hegen, H; Guger, M; Harrer, A; Hoelzl, M; Kraus, J; Skrobal, A; Schautzer, F; Schmidegg, S; Schocke, M; Deisenhammer, F;
Mult Scler Relat Disord. 2014; 3(2):220-226
Originalarbeiten (Zeitschrift)
A routine-qualified flow cytometric method for the identification of multiple sclerosis patients with reduced therapy efficiency under natalizumab
Oppermann, K; Harrer, A; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, E; Sellner, J; Deisenhammer, F; Trinka, E; Kraus, J
LABORATORIUMSMEDIZIN. 2014; 38(1): 17-23.
Originalarbeiten (Zeitschrift)
Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?
Wipfler, P; Harrer, A; Pilz, G; Oppermann, K; Afazel, S; Haschke-Becher, E; Sellner, J; Trinka, E; Kraus, J;
Acta Neurol Scand. 2014; 129(3):e12-e15
Originalarbeiten (Zeitschrift)
Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen
Natalizumab and fingolimod differentially impact the alpha-4/beta-1 and alpha-L/beta-2 expression-related subset diversity of T-cells
Harrer, A; Oppermann, K; Wanek, J; Pilz, G; Wipfler, P; Sellner, J; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J
MULT SCLER J. 2014; 20: 333-333.
Abstracts (Zeitschrift)
Importance of CSF analysis in the era of McDonald 2010 criteria: a retrospective multicenter study in patients with a clinically isolated syndrome
Tumani, H; Trebst, C; Spreer, A; Borisow, N; Harrer, A; Brecht, I; Buttmann, M; Balint, B; Stich, O; Schlegel, S; Winkelmann, A; Roesler, R; Lauda, F; Huss, A; Yildiz, O; Voss, E; Muche, R; Rauer, S; Bergh, FT; Paul, F; Wildemann, B; Kraus, J; Ruprecht, K; Stangel, M; Otto, M; Zettl, UK
MULT SCLER J. 2014; 20: 155-156.
Abstracts (Zeitschrift)
2013
Beiträge in Fachzeitschriften
Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy.
Harrer, A; Tumani, H; Niendorf, S; Lauda, F; Geis, C; Weishaupt, A; Kleinschnitz, C; Rauer, S; Kuhle, J; Stangel, M; Weber, F; Uhr, M; Linnebank, M; Wildemann, B; Jarius, S; Guger, M; Ayzenberg, I; Chan, A; Zettl, U; Wiendl, H; Pilz, G; Hitzl, W; Weber, JR; Kraus, J;
Mult Scler. 2013; 19(9):1209-1212
Originalarbeiten (Zeitschrift)
Tumefactive MS lesions under fingolimod: a case report and literature review.
Pilz, G; Harrer, A; Wipfler, P; Oppermann, K; Sellner, J; Fazekas, F; Trinka, E; Kraus, J;
Neurology. 2013; 81(19): 1654-1658.
Originalarbeiten (Zeitschrift)
Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis.
Sellner, J; Koczi, W; Harrer, A; Oppermann, K; Obregon-Castrillo, E; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J;
Clin Exp Immunol. 2013; 173(3):381-389
Originalarbeiten (Zeitschrift)
Circadian rhythmicity of inflammatory serum parameters: a neglected issue in the search of biomarkers in multiple sclerosis.
Wipfler, P; Heikkinen, A; Harrer, A; Pilz, G; Kunz, A; Golaszewski, SM; Reuss, R; Oschmann, P; Kraus, J;
J Neurol. 2013; 260(1):221-227
Originalarbeiten (Zeitschrift)
Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen
Shift in the CD4+/CD8+ratio of cerebrospinal fluid T cells independent from free or cell-bound natalizumab
Harrer, A; Oppermann, K; Pizl, G; Wipfler, P; Sellner, J; Hitzl, W; Haschke-Becher, E; Afazel, S; Rispens, T; van der Kleij, D; Trinka, E; Kraus, J
MULT SCLER J. 2013; 19(11): 451-452.
Abstracts (Zeitschrift)
Flow-cytometry and the detection of natalizumab-neutralizing antibodies in multiple sclerosis
Oppermann, K; Harrer, A; Pilz, G; Wipfler, P; Holl, B; Deisenhammer, F; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J
MULT SCLER J. 2013; 19(11): 500-501.
Abstracts (Zeitschrift)
2012
Beiträge in Fachzeitschriften
Isolated leptomeningeal infiltration of a primary CNS B-cell lymphoma diagnosed by flow cytometry and confirmed by necropsy.
Broussalis, E; Hutterer, M; Oppermann, K; Wipfler, P; Pilz, G; Harrer, A; Haschke-Becher, E; Golaszewski, S; Schönauer, U; Weis, S; Killer-Oberpfalzer, M; Mc Coy, M; Trinka, E; Kraus, J;
Acta Neurol Scand. 2012; 126(3):e11-e16
Fallberichte
Current therapies in ischemic stroke. Part A. Recent developments in acute stroke treatment and in stroke prevention.
Broussalis, E; Killer, M; McCoy, M; Harrer, A; Trinka, E; Kraus, J;
Drug Discov Today. 2012; 17(7-8):296-309
Übersichtsarbeiten
Current therapies in ischemic stroke. Part B. Future candidates in stroke therapy and experimental studies.
Broussalis, E; Trinka, E; Killer, M; Harrer, A; McCoy, M; Kraus, J;
Drug Discov Today. 2012; 17(13-14):671-684
Übersichtsarbeiten
Flow cytometry and drug monitoring of natalizumab saturation of immune cells in multiple sclerosis
Harrer, A; Oppermann, K; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, L; Trinka, E; Kraus, J
LABORATORIUMSMEDIZIN. 2012; 36(6): 377-382.
Originalarbeiten (Zeitschrift)
Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis.
Harrer, A; Pilz, G; Einhaeupl, M; Oppermann, K; Hitzl, W; Wipfler, P; Sellner, J; Golaszewski, S; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J;
PLoS One. 2012; 7(2):e31784
Originalarbeiten (Zeitschrift)
Overview of laboratory methods to monitor innovative treatment regimens in multiple sclerosis
Kraus, J; Pilz, G; Wipfler, P; Holl, B; Oppermann, K; Golaszewski, SM; Harrer, A
LABORATORIUMSMEDIZIN. 2012; 36(6): 389-396.
Übersichtsarbeiten
Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodies.
Pilz, G; Harrer, A; Oppermann, K; Wipfler, P; Golaszewski, S; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J;
Mult Scler. 2012; 18(4):506-509
Originalarbeiten (Zeitschrift)
Future relevance of CSF biomarkers in modern MS treatment
Pilz, G; Wipfler, P; Harrer, A; Holl, B; Oppermann, K; Golaszewski, SM; Trinka, E; Kraus, J
LABORATORIUMSMEDIZIN. 2012; 36(6): 383-388.
Originalarbeiten (Zeitschrift)
2011
Beiträge in Fachzeitschriften
Molecular characterization of Api g 2, a novel allergenic member of the lipid-transfer protein 1 family from celery stalks.
Gadermaier, G; Egger, M; Girbl, T; Erler, A; Harrer, A; Vejvar, E; Liso, M; Richter, K; Zuidmeer, L; Mari, A; Ferreira, F;
Mol Nutr Food Res. 2011; 55(4): 568-577.
Originalarbeiten (Zeitschrift)
Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells.
Harrer, A; Wipfler, P; Einhaeupl, M; Pilz, G; Oppermann, K; Hitzl, W; Afazel, S; Haschke-Becher, E; Strasser, P; Trinka, E; Kraus, J;
J Neuroimmunol. 2011; 234(1-2):148-154
Originalarbeiten (Zeitschrift)
Basophil activation test for investigation of IgE-mediated mechanisms in drug hypersensitivity.
Steiner, M; Harrer, A; Lang, R; Schneider, M; Ferreira, T; Hawranek, T; Himly, M;
J Vis Exp. 2011;
Originalarbeiten (Zeitschrift)
Reshaping the Bet v 1 fold modulates T(H) polarization.
Wallner, M; Hauser, M; Himly, M; Zaborsky, N; Mutschlechner, S; Harrer, A; Asam, C; Pichler, U; van Ree, R; Briza, P; Thalhamer, J; Bohle, B; Achatz, G; Ferreira, F
J ALLERGY CLIN IMMUN. 2011; 127(6): 1571-8.e9.
Originalarbeiten (Zeitschrift)
Recent developments in approved and oral multiple sclerosis treatment and an update on future treatment options.
Wipfler, P; Harrer, A; Pilz, G; Oppermann, K; Trinka, E; Kraus, J;
Drug Discov Today. 2011; 16(1-2):8-21
Übersichtsarbeiten
Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
Wipfler, P; Oppermann, K; Pilz, G; Afazel, S; Haschke-Becher, E; Harrer, A; Huemer, M; Kunz, A; Golaszewski, S; Staffen, W; Ladurner, G; Kraus, J;
Mult Scler. 2011; 17(1):16-23
Originalarbeiten (Zeitschrift)
2010
Beiträge in Fachzeitschriften
Characterization of plant food allergens: an overview on physicochemical and immunological techniques.
Harrer, A; Egger, M; Gadermaier, G; Erler, A; Hauser, M; Ferreira, F; Himly, M;
Mol Nutr Food Res. 2010; 54(1): 93-112.
Übersichtsarbeiten
Diclofenac Hypersensitivity: Antibody Responses to the Parent Drug and Relevant Metabolites
Harrer, A; Lang, R; Grims, R; Braitsch, M; Hawranek, T; Aberer, W; Vogel, L; Schmid, W; Ferreira, F; Himly, M
PLOS ONE. 2010; 5(10): e13707
Originalarbeiten (Zeitschrift)
Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen
Continuous Down-Regulation of VLA-4 and Accumulation of Natalizumab at the VLA-4 Receptor: Potential Molecular Basis of Enhanced Treatment Efficacy and Occurrence of Opportunistic Infections
Kraus, J; Oppermann, K; Wipfler, P; Pilz, G; Harrer, A; Afazel, S; Haschke-Becher, E; Kunz, AB; Golaszewski, SM; Staffen, W; Ladurner, G
NEUROLOGY. 2010; 74(9): A416-A416.
Abstracts (Zeitschrift)
Short- and long-term decrease of soluble adhesion molecules (sICAM-1,-2,-3 and sVCAM-1) during natalizumab treatment
Oppermann, K; Pilz, G; Wipfler, P; Harrer, A; Sulzer, C; Afazel, S; Haschke-Becher, E; Ladurner, G; Kraus, J
J NEUROL. 2010; 257: S220-S220.
Abstracts (Zeitschrift)
Expression levels of cell surface bound interferon-receptor remain stable during short- and long-term interferon beta-1b treatment
Oppermann, K; Wipfler, P; Pilz, G; Harrer, A; Duerr, EM; Koczi, W; Sulzer, C; Afazel, S; Haschke-Becher, E; Ladurner, G; Kraus, J
J NEUROL. 2010; 257: S219-S219.
Abstracts (Zeitschrift)
Accumulation of natalizumab at the VLA-4 receptor as a potential molecular basis of enhanced treatment efficacy and occurrence of opportunistic infections
Wipfler, P; Oppermann, K; Pilz, G; Harrer, A; Haschke-Becher, E; Kunz, A; Golaszewski, S; Ladurner, G; Kraus, J
J NEUROL. 2010; 257: S8-S8.
Abstracts (Zeitschrift)
2009
Beiträge in Fachzeitschriften
Isoform identification and characterization of Art v 3, the lipid-transfer protein of mugwort pollen.
Gadermaier, G; Harrer, A; Girbl, T; Palazzo, P; Himly, M; Vogel, L; Briza, P; Mari, A; Ferreira, F
Mol Immunol. 2009; 46(10):1919-1924
Originalarbeiten (Zeitschrift)
2007
Publizierte (zitierfähige) Beiträge für wissenschaftliche Veranstaltungen
Frequency of COMT Val108/158Met-polymorphism for a schizophrenia sick patient with positive and/or negative Cannabis anamnesis - A pilot study
Egger, C; Muhlbacher, M; Buschmann, W; Stelzig, R; Strasser, P; Nickel, M; Wolfgang, H; Harrer, A; Ladurner, G; Stuppack, C
NERVENARZT. 2007; 78: 288-288.
Abstracts (Zeitschrift)